Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ONC 841 |
| Synonyms | |
| Therapy Description |
ONC 841 is a monoclonal antibody targeting Siglec10, which potentially activates immune cells and relieves Siglec-10-mediated inhibition of tumor cell phagocytosis, leading to increased tumor cell killing (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ONC 841 | ONC841|ONC-841 | ONC 841 is a monoclonal antibody targeting Siglec10, which potentially activates immune cells and relieves Siglec-10-mediated inhibition of tumor cell phagocytosis, leading to increased tumor cell killing (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06352359 | Phase I | ONC 841 | Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors | Recruiting | USA | 0 |